Evidence Summary
- Evidence Level
- Preliminary
- Mechanism
- Enrollment: Actual, Sponsor Type: Other, Unknown / General
- Safety
- Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
- Dosing
- See linked studies/trials for reported doses and durations; typical protocols vary widely.
GLP-1/GIP agonist early Long COVID trials (metabolic/anti-inflammatory). Weekly titrated injection. GI side effects, cost. May benefit overweight subsets. Very early.
Clinical Trials
1 trial(s) registered
| NCT ID | Title | Phase | Status |
|---|---|---|---|
| NCT07128082 | The Long COVID Treatment Trial | Phase 2 | Active, not recruiting |
Key Studies / References
- See linked studies